Syntara the science explained, page-182

I think everyone here does expect a cap raise at some point in the new year. Would have just under $10mil right now. The conference should generate a lot of interest and depending on how robust the P2 Data is we would want to have a good cash position going into any future negotiations regarding buyout. I don't think pharma will throw down big coin until a larger cohort gets stress tested so most likely path is cap raise and a licensing deal at some point following the conference. We are still significantly undervalued though, especially when you do a market cap peer comparison and then throw in the potential buyout figures. Very early if this plays out how we all hope it does.